研究员,药物化学/Research Investigator, Medchem(博士)当面告知

百濟神州有限公司
2026-12-15 15:28:34
校招博士27届

岗位详情

地区:

北京

专业要求:

专业不限

岗位职责:

投递此岗位,请务必在简历中附上您过往合成路线的研究总结。 Responsibilities: The candidate will be responsible for • syntheric route design / trouble shooting and efficient synthesis of assigned molecules to enable medchem multi-dimensional SAR investigations; • gradual learning on general medicinal chemistry / structure based drug design to enable effective medchem design balancing drug-like properties; • assisting chemistry leader on team wise synthetic trouble shooting; • potentially functioning as medchem representative for cross-function communications. Qualifications: • PhD research on synthetic organic chemistry (preferably total synthesis of natural product); • track record on successful problem solving of synthetic issues; • logically clear with both big picture in mind and details oriented during problem solving; • good team player with collaborative attitude; • good learning agility for new stuffs; • ability for English communication and presentation

招聘要求:

投递此岗位,请务必在简历中附上您过往合成路线的研究总结。 Responsibilities: The candidate will be responsible for • syntheric route design / trouble shooting and efficient synthesis of assigned molecules to enable medchem multi-dimensional SAR investigations; • gradual learning on general medicinal chemistry / structure based drug design to enable effective medchem design balancing drug-like properties; • assisting chemistry leader on team wise synthetic trouble shooting; • potentially functioning as medchem representative for cross-function communications. Qualifications: • PhD research on synthetic organic chemistry (preferably total synthesis of natural product); • track record on successful problem solving of synthetic issues; • logically clear with both big picture in mind and details oriented during problem solving; • good team player with collaborative attitude; • good learning agility for new stuffs; • ability for English communication and presentation

公司介绍

百濟神州有限公司

百濟神州有限公司

百濟神州有限公司,成立于2018-06-28,位于香港,登记状态:仍注册,注册资本15.4142万美元,公司类型:中外合资

百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物,其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可,包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物,该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月,公司拥有一支超过1300名员工的全球团队,成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。